Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma - PubMed (original) (raw)
. 2008 Oct 16;455(7215):967-70.
doi: 10.1038/nature07398.
Delphine Lequin, Laurence Brugières, Agnès Ribeiro, Loïc de Pontual, Valérie Combaret, Virginie Raynal, Alain Puisieux, Gudrun Schleiermacher, Gaëlle Pierron, Dominique Valteau-Couanet, Thierry Frebourg, Jean Michon, Stanislas Lyonnet, Jeanne Amiel, Olivier Delattre
Affiliations
- PMID: 18923523
- DOI: 10.1038/nature07398
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix-Lerosey et al. Nature. 2008.
Abstract
Neuroblastoma, a tumour derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumours in childhood. It usually occurs sporadically but familial cases are observed, with a subset of cases occurring in association with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene. Here we conducted genome-wide comparative genomic hybridization analysis on a large series of neuroblastomas. Copy number increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was observed recurrently. One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development. Through subsequent direct sequencing of cell lines and primary tumour DNAs we identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots. Germline mutations were observed in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene. Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity. The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation. Altogether, these data identify ALK as a critical player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.
Comment in
- Cancer: A ringleader identified.
Eng C. Eng C. Nature. 2008 Oct 16;455(7215):883-4. doi: 10.1038/455883a. Nature. 2008. PMID: 18923503 No abstract available.
Similar articles
- Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S. Chen Y, et al. Nature. 2008 Oct 16;455(7215):971-4. doi: 10.1038/nature07399. Nature. 2008. PMID: 18923524 - Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R. Passoni L, et al. Cancer Res. 2009 Sep 15;69(18):7338-46. doi: 10.1158/0008-5472.CAN-08-4419. Epub 2009 Sep 1. Cancer Res. 2009. PMID: 19723661 - Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. George RE, et al. Nature. 2008 Oct 16;455(7215):975-8. doi: 10.1038/nature07397. Nature. 2008. PMID: 18923525 Free PMC article. - The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC, McDermott R. Kelleher FC, et al. Eur J Cancer. 2010 Sep;46(13):2357-68. doi: 10.1016/j.ejca.2010.04.006. Epub 2010 May 5. Eur J Cancer. 2010. PMID: 20451371 Review. - Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.
Bourdeaut F, Trochet D, Janoueix-Lerosey I, Ribeiro A, Deville A, Coz C, Michiels JF, Lyonnet S, Amiel J, Delattre O. Bourdeaut F, et al. Cancer Lett. 2005 Oct 18;228(1-2):51-8. doi: 10.1016/j.canlet.2005.01.055. Cancer Lett. 2005. PMID: 15949893 Review.
Cited by
- Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis.
Han M, Niu H, Duan F, Wang Z, Zhang Z, Ren H. Han M, et al. Front Oncol. 2024 Oct 10;14:1383805. doi: 10.3389/fonc.2024.1383805. eCollection 2024. Front Oncol. 2024. PMID: 39450262 Free PMC article. - Altered methylation of imprinted genes in neuroblastoma: implications for prognostic refinement.
Suman M, Löfgren M, Fransson S, Yousuf JI, Svensson J, Djos A, Martinsson T, Kogner P, Kling T, Carén H. Suman M, et al. J Transl Med. 2024 Aug 31;22(1):808. doi: 10.1186/s12967-024-05634-5. J Transl Med. 2024. PMID: 39217334 Free PMC article. - Identification of a ferroptosis-related gene signature for the prognosis of pediatric neuroblastoma.
Lin X, Shao K, Lin Z, Liang Q, Li X, Chen H, Wu J. Lin X, et al. Transl Cancer Res. 2024 Jul 31;13(7):3678-3694. doi: 10.21037/tcr-24-269. Epub 2024 Jul 26. Transl Cancer Res. 2024. PMID: 39145053 Free PMC article. - Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma.
Sundaramoorthy S, Colombo DF, Sanalkumar R, Broye L, Balmas Bourloud K, Boulay G, Cironi L, Stamenkovic I, Renella R, Kuttler F, Turcatti G, Rivera MN, Mühlethaler-Mottet A, Bardet AF, Riggi N. Sundaramoorthy S, et al. JCI Insight. 2024 Jul 22;9(14):e169647. doi: 10.1172/jci.insight.169647. JCI Insight. 2024. PMID: 39133652 Free PMC article. - Lysophosphatidic Acid Stimulates Mitogenic Activity and Signaling in Human Neuroblastoma Cells through a Crosstalk with Anaplastic Lymphoma Kinase.
Dedoni S, Olianas MC, Onali P. Dedoni S, et al. Biomolecules. 2024 May 28;14(6):631. doi: 10.3390/biom14060631. Biomolecules. 2024. PMID: 38927035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials